effect overlay
activetrials
Epilepsy

A Randomized, Double-blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Safety, Tolerability, and Efficacy of XEN1101 as Adjunctive Therapy in Focal-Onset Seizures
 

HREC: 2023.062
Principal Investigator: Dr John-Paul Nicolo
Coordinator contact: Karen Chidgey
Funding: Commercial
Epilepsy

A Randomized, Double-blind, Placebo-Controlled, Multicenter, Phase 3 Study to Evaluate the Safety, Tolerability, and Efficacy of XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures
 

HREC: 2023.063
Principal Investigator: Dr John-Paul Nicolo
Coordinator contact: Karen Chidgey
Funding: Commercial
Epilepsy

A Multicenter, Open-label, Long-term, Safety, Tolerability, and Efficacy Study of XEN1101 in Adults Diagnosed With Epilepsy
 

HREC: 2023.064
Principal Investigator: Dr John-Paul Nicolo
Coordinator contact: Karen Chidgey
Funding: Commercial

A Phase 2, Randomised, Controlled Trial of Sodium Selenate as a Disease-modifying Treatment for Chronic Drug-resistant Temporal Lobe Epilepsy 
 

HREC: 2023.153
Principal Investigator: Dr John-Paul Nicolo
Coordinator contact: Lei Chen
Funding: Non-Commercial

A Phase 3, Open-label Study of Adjunctive Ganaxolone (GNX) Treatment in Children and Adults with Tuberous Sclerosis Complex (TSC)-related Epilepsy
 

HREC: 2024.062
Principal Investigator: Dr John-Paul Nicolo
Coordinator contact: Elle Hurley
Funding: Commercial